Loading briefing details...
News Brief
By: PointLine Media Research & Editorial Team
Category:Business,Education,Industry,Lifestyle,Technology
November 12, 2026
This announcement highlights a critical vulnerability in the global biotech market: the failure to align international drug development with US commercial realities. By formalizing the Landing Gap, Resilient Performance Group provides a necessary framework for investors and developers to mitigate financial risk and ensure successful, sustainable drug commercialization.
Pharmaceutical companies are increasingly acquiring international drug candidates at record volumes, yet a significant commercial disconnect persists. Brian Baldari, founder of Resilient Performance Group, has officially identified this phenomenon as the Landing Gap—the overlooked commercial exposure that occurs when an asset developed under one regulatory and payer system is suddenly forced into the complexities of a US launch.
As cross-border licensing deals surged to $137.7 billion by 2025, diligence remains heavily focused on scientific viability rather than downstream commercial execution. According to Baldari, organizations often fail to price for whether a development program truly supports a US label, survives rigorous payer scrutiny, or maintains the necessary value proposition within the competitive United States channel.
To address these challenges, Resilient Performance Group has formalized its Cross-Border Commercial Readiness practice. By leveraging dual-perspective expertise in global strategy and US general management, the firm provides essential counsel to C-suite executives and investors. This strategic guidance ensures that clinical assets successfully transition from international origin markets to high-value commercial success in the United States.